MoneyWorks4Me

Balaxi Pharma. - Quaterly Results

05 Nov 2024 Evaluate
The sales moved up 27.81% to Rs. 211.55 millions for the September 2024 quarter as compared to Rs. 165.52 millions during the year-ago period.An average growth of 40.52% was recorded for the quarter ended September 2024 to Rs. 16.61  millions from Rs. 11.82 millions.Operating profit for the quarter ended September 2024 rose to 27.69 millions as compared to 20.65 millions of corresponding quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 211.55 165.52 27.81 401.81 415.92 -3.39 701.96 1081.38 -35.09
Other Income 12.91 11.53 11.97 21.36 12.79 67.01 23.99 66.04 -63.67
PBIDT 27.69 20.65 34.09 51.25 59.62 -14.04 76.35 234.26 -67.41
Interest 4.49 3.62 24.03 8.03 6.20 29.52 15.41 4.59 235.73
PBDT 23.20 17.03 36.23 43.22 53.42 -19.09 60.94 229.67 -73.47
Depreciation 1.16 1.32 -12.12 2.31 2.63 -12.17 5.11 5.15 -0.78
PBT 22.04 15.71 40.29 40.91 50.79 -19.45 55.83 224.52 -75.13
TAX 5.43 3.89 39.59 10.54 13.43 -21.52 19.33 62.29 -68.97
Deferred Tax -0.19 -0.03 533.33 -0.38 -0.06 533.33 -1.05 10.62 -109.89
PAT 16.61 11.82 40.52 30.37 37.36 -18.71 36.50 162.23 -77.50
Equity 110.42 102.30 7.94 110.42 102.30 7.94 108.98 101.81 7.04
PBIDTM(%) 13.09 12.48 4.92 12.75 14.33 -11.02 10.88 21.66 -49.79
Peers